nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Epirubicin—prostate cancer	0.166	0.444	CbGbCtD
Orlistat—CYP3A4—prostate cancer	0.136	1	CbGaD
Orlistat—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.043	0.115	CbGbCtD
Orlistat—CYP3A4—Bicalutamide—prostate cancer	0.0226	0.0604	CbGbCtD
Orlistat—CYP3A4—Estramustine—prostate cancer	0.021	0.0561	CbGbCtD
Orlistat—CYP3A4—Abiraterone—prostate cancer	0.0187	0.05	CbGbCtD
Orlistat—CYP3A4—Flutamide—prostate cancer	0.0187	0.05	CbGbCtD
Orlistat—CYP3A4—Cabazitaxel—prostate cancer	0.0138	0.037	CbGbCtD
Orlistat—CYP3A4—Estrone—prostate cancer	0.0135	0.0362	CbGbCtD
Orlistat—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0121	0.0322	CbGbCtD
Orlistat—CYP3A4—Conjugated Estrogens—prostate cancer	0.00885	0.0237	CbGbCtD
Orlistat—CYP3A4—Mitoxantrone—prostate cancer	0.00804	0.0215	CbGbCtD
Orlistat—CYP3A4—Estradiol—prostate cancer	0.00777	0.0208	CbGbCtD
Orlistat—DAGLB—prostate gland—prostate cancer	0.00693	0.0728	CbGeAlD
Orlistat—CYP3A4—Prednisone—prostate cancer	0.00668	0.0179	CbGbCtD
Orlistat—LIPF—testis—prostate cancer	0.00611	0.0642	CbGeAlD
Orlistat—PLA2G7—prostate gland—prostate cancer	0.00559	0.0588	CbGeAlD
Orlistat—ABHD16A—prostate gland—prostate cancer	0.00525	0.0552	CbGeAlD
Orlistat—CYP3A4—Etoposide—prostate cancer	0.00507	0.0136	CbGbCtD
Orlistat—ABHD12—prostate gland—prostate cancer	0.00492	0.0517	CbGeAlD
Orlistat—PLA2G7—seminal vesicle—prostate cancer	0.00473	0.0497	CbGeAlD
Orlistat—CYP3A4—Docetaxel—prostate cancer	0.00464	0.0124	CbGbCtD
Orlistat—ABHD16A—seminal vesicle—prostate cancer	0.00444	0.0467	CbGeAlD
Orlistat—ABHD12—seminal vesicle—prostate cancer	0.00416	0.0437	CbGeAlD
Orlistat—FASN—prostate gland—prostate cancer	0.00413	0.0434	CbGeAlD
Orlistat—DAGLA—testis—prostate cancer	0.00394	0.0414	CbGeAlD
Orlistat—ABHD16A—urethra—prostate cancer	0.00351	0.0369	CbGeAlD
Orlistat—FASN—seminal vesicle—prostate cancer	0.00349	0.0367	CbGeAlD
Orlistat—CYP3A4—Doxorubicin—prostate cancer	0.00346	0.00925	CbGbCtD
Orlistat—ABHD12—urethra—prostate cancer	0.00329	0.0346	CbGeAlD
Orlistat—DAGLB—testis—prostate cancer	0.00305	0.0321	CbGeAlD
Orlistat—PLA2G7—bone marrow—prostate cancer	0.00288	0.0303	CbGeAlD
Orlistat—ABHD16A—bone marrow—prostate cancer	0.00271	0.0284	CbGeAlD
Orlistat—ABHD16A—testis—prostate cancer	0.00231	0.0243	CbGeAlD
Orlistat—DAGLB—lymph node—prostate cancer	0.00221	0.0232	CbGeAlD
Orlistat—ABHD12—testis—prostate cancer	0.00217	0.0228	CbGeAlD
Orlistat—PLA2G4A—prostate gland—prostate cancer	0.00198	0.0209	CbGeAlD
Orlistat—CYP3A4—urine—prostate cancer	0.00182	0.0192	CbGeAlD
Orlistat—FASN—testis—prostate cancer	0.00182	0.0191	CbGeAlD
Orlistat—PLA2G7—lymph node—prostate cancer	0.00179	0.0188	CbGeAlD
Orlistat—PLA2G4A—seminal vesicle—prostate cancer	0.00168	0.0176	CbGeAlD
Orlistat—ABHD16A—lymph node—prostate cancer	0.00168	0.0176	CbGeAlD
Orlistat—ABHD12—lymph node—prostate cancer	0.00157	0.0165	CbGeAlD
Orlistat—PLA2G4A—renal system—prostate cancer	0.00135	0.0142	CbGeAlD
Orlistat—PLA2G4A—urethra—prostate cancer	0.00133	0.014	CbGeAlD
Orlistat—FASN—lymph node—prostate cancer	0.00132	0.0139	CbGeAlD
Orlistat—PLA2G4A—bone marrow—prostate cancer	0.00102	0.0107	CbGeAlD
Orlistat—PLA2G4A—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000917	0.262	CbGdCrCtD
Orlistat—PLA2G4A—testis—prostate cancer	0.000874	0.00919	CbGeAlD
Orlistat—PLA2G4A—Estradiol—Estramustine—prostate cancer	0.000779	0.223	CbGdCrCtD
Orlistat—PLA2G4A—lymph node—prostate cancer	0.000634	0.00666	CbGeAlD
Orlistat—PLA2G4A—Estradiol—Estrone—prostate cancer	0.000619	0.177	CbGdCrCtD
Orlistat—PLA2G4A—Estradiol—Conjugated Estrogens—prostate cancer	0.000545	0.156	CbGdCrCtD
Orlistat—PLA2G4A—Estradiol—Ethinyl Estradiol—prostate cancer	0.000458	0.131	CbGdCrCtD
Orlistat—CYP3A4—renal system—prostate cancer	0.000446	0.00469	CbGeAlD
Orlistat—Ethanolamine Oleate—CYP2E1—prostate cancer	0.000296	1	CrCbGaD
Orlistat—PLA2G4A—Betamethasone—Prednisone—prostate cancer	8.96e-05	0.0256	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Prednisone—prostate cancer	8.96e-05	0.0256	CbGdCrCtD
Orlistat—Upper respiratory tract infection—Doxorubicin—prostate cancer	6.28e-05	0.000284	CcSEcCtD
Orlistat—Myalgia—Capecitabine—prostate cancer	6.22e-05	0.000281	CcSEcCtD
Orlistat—Chest pain—Capecitabine—prostate cancer	6.22e-05	0.000281	CcSEcCtD
Orlistat—Anxiety—Capecitabine—prostate cancer	6.2e-05	0.00028	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	6.18e-05	0.000279	CcSEcCtD
Orlistat—Hepatobiliary disease—Epirubicin—prostate cancer	6.16e-05	0.000278	CcSEcCtD
Orlistat—Oedema—Docetaxel—prostate cancer	6.16e-05	0.000278	CcSEcCtD
Orlistat—Anaphylactic shock—Docetaxel—prostate cancer	6.16e-05	0.000278	CcSEcCtD
Orlistat—Discomfort—Capecitabine—prostate cancer	6.15e-05	0.000278	CcSEcCtD
Orlistat—Vision blurred—Prednisone—prostate cancer	6.14e-05	0.000277	CcSEcCtD
Orlistat—Infection—Docetaxel—prostate cancer	6.12e-05	0.000276	CcSEcCtD
Orlistat—Sinusitis—Epirubicin—prostate cancer	6.11e-05	0.000276	CcSEcCtD
Orlistat—Feeling abnormal—Etoposide—prostate cancer	6.11e-05	0.000276	CcSEcCtD
Orlistat—Diarrhoea—Mitoxantrone—prostate cancer	6.1e-05	0.000275	CcSEcCtD
Orlistat—Dry mouth—Capecitabine—prostate cancer	6.09e-05	0.000275	CcSEcCtD
Orlistat—Vomiting—Estradiol—prostate cancer	6.08e-05	0.000275	CcSEcCtD
Orlistat—Gastrointestinal pain—Etoposide—prostate cancer	6.06e-05	0.000274	CcSEcCtD
Orlistat—Nervous system disorder—Docetaxel—prostate cancer	6.04e-05	0.000273	CcSEcCtD
Orlistat—Ill-defined disorder—Prednisone—prostate cancer	6.04e-05	0.000273	CcSEcCtD
Orlistat—Rash—Estradiol—prostate cancer	6.03e-05	0.000272	CcSEcCtD
Orlistat—Infestation—Doxorubicin—prostate cancer	6.03e-05	0.000272	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—prostate cancer	6.03e-05	0.000272	CcSEcCtD
Orlistat—Dermatitis—Estradiol—prostate cancer	6.03e-05	0.000272	CcSEcCtD
Orlistat—Headache—Estradiol—prostate cancer	5.99e-05	0.000271	CcSEcCtD
Orlistat—Skin disorder—Docetaxel—prostate cancer	5.98e-05	0.00027	CcSEcCtD
Orlistat—Oedema—Capecitabine—prostate cancer	5.97e-05	0.000269	CcSEcCtD
Orlistat—Angioedema—Prednisone—prostate cancer	5.95e-05	0.000269	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—prostate cancer	5.93e-05	0.000268	CcSEcCtD
Orlistat—Infection—Capecitabine—prostate cancer	5.93e-05	0.000268	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—prostate cancer	5.91e-05	0.000267	CcSEcCtD
Orlistat—Urticaria—Etoposide—prostate cancer	5.89e-05	0.000266	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—prostate cancer	5.88e-05	0.000266	CcSEcCtD
Orlistat—Malaise—Prednisone—prostate cancer	5.87e-05	0.000265	CcSEcCtD
Orlistat—Abdominal pain—Etoposide—prostate cancer	5.86e-05	0.000265	CcSEcCtD
Orlistat—Body temperature increased—Etoposide—prostate cancer	5.86e-05	0.000265	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—prostate cancer	5.86e-05	0.000265	CcSEcCtD
Orlistat—Nervous system disorder—Capecitabine—prostate cancer	5.85e-05	0.000264	CcSEcCtD
Orlistat—Vertigo—Prednisone—prostate cancer	5.85e-05	0.000264	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—prostate cancer	5.85e-05	0.000264	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—prostate cancer	5.85e-05	0.000264	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—prostate cancer	5.81e-05	0.000262	CcSEcCtD
Orlistat—Skin disorder—Capecitabine—prostate cancer	5.79e-05	0.000262	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—prostate cancer	5.78e-05	0.000261	CcSEcCtD
Orlistat—Hyperhidrosis—Capecitabine—prostate cancer	5.77e-05	0.00026	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—prostate cancer	5.76e-05	0.00026	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—prostate cancer	5.73e-05	0.000259	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—prostate cancer	5.7e-05	0.000258	CcSEcCtD
Orlistat—Nausea—Estradiol—prostate cancer	5.68e-05	0.000257	CcSEcCtD
Orlistat—Vomiting—Mitoxantrone—prostate cancer	5.67e-05	0.000256	CcSEcCtD
Orlistat—Sinusitis—Doxorubicin—prostate cancer	5.66e-05	0.000255	CcSEcCtD
Orlistat—Convulsion—Prednisone—prostate cancer	5.64e-05	0.000255	CcSEcCtD
Orlistat—Rash—Mitoxantrone—prostate cancer	5.62e-05	0.000254	CcSEcCtD
Orlistat—Dermatitis—Mitoxantrone—prostate cancer	5.61e-05	0.000254	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Docetaxel—prostate cancer	5.61e-05	0.000254	CcSEcCtD
Orlistat—Headache—Mitoxantrone—prostate cancer	5.58e-05	0.000252	CcSEcCtD
Orlistat—Insomnia—Docetaxel—prostate cancer	5.57e-05	0.000252	CcSEcCtD
Orlistat—Myalgia—Prednisone—prostate cancer	5.54e-05	0.00025	CcSEcCtD
Orlistat—Paraesthesia—Docetaxel—prostate cancer	5.53e-05	0.00025	CcSEcCtD
Orlistat—Anxiety—Prednisone—prostate cancer	5.52e-05	0.000249	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.5e-05	0.000249	CcSEcCtD
Orlistat—Discomfort—Prednisone—prostate cancer	5.48e-05	0.000247	CcSEcCtD
Orlistat—Hypersensitivity—Etoposide—prostate cancer	5.46e-05	0.000247	CcSEcCtD
Orlistat—Haemoglobin—Doxorubicin—prostate cancer	5.44e-05	0.000246	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.43e-05	0.000245	CcSEcCtD
Orlistat—Dyspepsia—Docetaxel—prostate cancer	5.42e-05	0.000245	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—prostate cancer	5.41e-05	0.000244	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—prostate cancer	5.41e-05	0.000244	CcSEcCtD
Orlistat—Insomnia—Capecitabine—prostate cancer	5.4e-05	0.000244	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—prostate cancer	5.37e-05	0.000243	CcSEcCtD
Orlistat—Paraesthesia—Capecitabine—prostate cancer	5.36e-05	0.000242	CcSEcCtD
Orlistat—Decreased appetite—Docetaxel—prostate cancer	5.36e-05	0.000242	CcSEcCtD
Orlistat—Urinary tract disorder—Doxorubicin—prostate cancer	5.35e-05	0.000241	CcSEcCtD
Orlistat—Oedema peripheral—Doxorubicin—prostate cancer	5.33e-05	0.000241	CcSEcCtD
Orlistat—Gastrointestinal disorder—Docetaxel—prostate cancer	5.32e-05	0.00024	CcSEcCtD
Orlistat—Asthenia—Etoposide—prostate cancer	5.32e-05	0.00024	CcSEcCtD
Orlistat—Oedema—Prednisone—prostate cancer	5.31e-05	0.00024	CcSEcCtD
Orlistat—Anaphylactic shock—Prednisone—prostate cancer	5.31e-05	0.00024	CcSEcCtD
Orlistat—Fatigue—Docetaxel—prostate cancer	5.31e-05	0.00024	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—prostate cancer	5.31e-05	0.00024	CcSEcCtD
Orlistat—Nausea—Mitoxantrone—prostate cancer	5.29e-05	0.000239	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—prostate cancer	5.28e-05	0.000239	CcSEcCtD
Orlistat—Infection—Prednisone—prostate cancer	5.28e-05	0.000238	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—prostate cancer	5.27e-05	0.000238	CcSEcCtD
Orlistat—Pain—Docetaxel—prostate cancer	5.27e-05	0.000238	CcSEcCtD
Orlistat—Dyspepsia—Capecitabine—prostate cancer	5.25e-05	0.000237	CcSEcCtD
Orlistat—Pruritus—Etoposide—prostate cancer	5.25e-05	0.000237	CcSEcCtD
Orlistat—Nervous system disorder—Prednisone—prostate cancer	5.21e-05	0.000235	CcSEcCtD
Orlistat—Decreased appetite—Capecitabine—prostate cancer	5.19e-05	0.000234	CcSEcCtD
Orlistat—Alopecia—Epirubicin—prostate cancer	5.17e-05	0.000233	CcSEcCtD
Orlistat—Skin disorder—Prednisone—prostate cancer	5.16e-05	0.000233	CcSEcCtD
Orlistat—Gastrointestinal disorder—Capecitabine—prostate cancer	5.15e-05	0.000233	CcSEcCtD
Orlistat—Fatigue—Capecitabine—prostate cancer	5.14e-05	0.000232	CcSEcCtD
Orlistat—Hyperhidrosis—Prednisone—prostate cancer	5.14e-05	0.000232	CcSEcCtD
Orlistat—Mental disorder—Epirubicin—prostate cancer	5.12e-05	0.000231	CcSEcCtD
Orlistat—Pain—Capecitabine—prostate cancer	5.1e-05	0.00023	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—prostate cancer	5.09e-05	0.00023	CcSEcCtD
Orlistat—Feeling abnormal—Docetaxel—prostate cancer	5.08e-05	0.000229	CcSEcCtD
Orlistat—Diarrhoea—Etoposide—prostate cancer	5.07e-05	0.000229	CcSEcCtD
Orlistat—Gastrointestinal pain—Docetaxel—prostate cancer	5.04e-05	0.000228	CcSEcCtD
Orlistat—Flatulence—Epirubicin—prostate cancer	5.02e-05	0.000227	CcSEcCtD
Orlistat—Dysgeusia—Epirubicin—prostate cancer	4.99e-05	0.000225	CcSEcCtD
Orlistat—Back pain—Epirubicin—prostate cancer	4.93e-05	0.000222	CcSEcCtD
Orlistat—Feeling abnormal—Capecitabine—prostate cancer	4.92e-05	0.000222	CcSEcCtD
Orlistat—Dizziness—Etoposide—prostate cancer	4.9e-05	0.000221	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—prostate cancer	4.9e-05	0.000221	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—prostate cancer	4.89e-05	0.000221	CcSEcCtD
Orlistat—Gastrointestinal pain—Capecitabine—prostate cancer	4.88e-05	0.00022	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—prostate cancer	4.88e-05	0.00022	CcSEcCtD
Orlistat—Abdominal pain—Docetaxel—prostate cancer	4.87e-05	0.00022	CcSEcCtD
Orlistat—Body temperature increased—Docetaxel—prostate cancer	4.87e-05	0.00022	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Prednisone—prostate cancer	4.84e-05	0.000219	CcSEcCtD
Orlistat—Insomnia—Prednisone—prostate cancer	4.81e-05	0.000217	CcSEcCtD
Orlistat—Vision blurred—Epirubicin—prostate cancer	4.8e-05	0.000217	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—prostate cancer	4.78e-05	0.000216	CcSEcCtD
Orlistat—Paraesthesia—Prednisone—prostate cancer	4.77e-05	0.000215	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—prostate cancer	4.74e-05	0.000214	CcSEcCtD
Orlistat—Urticaria—Capecitabine—prostate cancer	4.74e-05	0.000214	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—prostate cancer	4.72e-05	0.000213	CcSEcCtD
Orlistat—Abdominal pain—Capecitabine—prostate cancer	4.72e-05	0.000213	CcSEcCtD
Orlistat—Body temperature increased—Capecitabine—prostate cancer	4.72e-05	0.000213	CcSEcCtD
Orlistat—Vomiting—Etoposide—prostate cancer	4.71e-05	0.000213	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—prostate cancer	4.71e-05	0.000213	CcSEcCtD
Orlistat—Dyspepsia—Prednisone—prostate cancer	4.68e-05	0.000211	CcSEcCtD
Orlistat—Rash—Etoposide—prostate cancer	4.67e-05	0.000211	CcSEcCtD
Orlistat—Dermatitis—Etoposide—prostate cancer	4.67e-05	0.000211	CcSEcCtD
Orlistat—Headache—Etoposide—prostate cancer	4.64e-05	0.00021	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—prostate cancer	4.64e-05	0.00021	CcSEcCtD
Orlistat—Decreased appetite—Prednisone—prostate cancer	4.62e-05	0.000209	CcSEcCtD
Orlistat—Dysgeusia—Doxorubicin—prostate cancer	4.61e-05	0.000208	CcSEcCtD
Orlistat—Malaise—Epirubicin—prostate cancer	4.59e-05	0.000207	CcSEcCtD
Orlistat—Fatigue—Prednisone—prostate cancer	4.58e-05	0.000207	CcSEcCtD
Orlistat—Vertigo—Epirubicin—prostate cancer	4.58e-05	0.000207	CcSEcCtD
Orlistat—Back pain—Doxorubicin—prostate cancer	4.56e-05	0.000206	CcSEcCtD
Orlistat—Hypersensitivity—Docetaxel—prostate cancer	4.54e-05	0.000205	CcSEcCtD
Orlistat—Muscle spasms—Doxorubicin—prostate cancer	4.53e-05	0.000205	CcSEcCtD
Orlistat—Palpitations—Epirubicin—prostate cancer	4.5e-05	0.000203	CcSEcCtD
Orlistat—Cough—Epirubicin—prostate cancer	4.44e-05	0.000201	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—prostate cancer	4.44e-05	0.000201	CcSEcCtD
Orlistat—Asthenia—Docetaxel—prostate cancer	4.42e-05	0.0002	CcSEcCtD
Orlistat—Convulsion—Epirubicin—prostate cancer	4.41e-05	0.000199	CcSEcCtD
Orlistat—Nausea—Etoposide—prostate cancer	4.4e-05	0.000199	CcSEcCtD
Orlistat—Hypersensitivity—Capecitabine—prostate cancer	4.4e-05	0.000198	CcSEcCtD
Orlistat—Feeling abnormal—Prednisone—prostate cancer	4.38e-05	0.000198	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—prostate cancer	4.37e-05	0.000197	CcSEcCtD
Orlistat—Pruritus—Docetaxel—prostate cancer	4.36e-05	0.000197	CcSEcCtD
Orlistat—Gastrointestinal pain—Prednisone—prostate cancer	4.35e-05	0.000196	CcSEcCtD
Orlistat—Myalgia—Epirubicin—prostate cancer	4.34e-05	0.000196	CcSEcCtD
Orlistat—Chest pain—Epirubicin—prostate cancer	4.34e-05	0.000196	CcSEcCtD
Orlistat—Anxiety—Epirubicin—prostate cancer	4.32e-05	0.000195	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.31e-05	0.000194	CcSEcCtD
Orlistat—Discomfort—Epirubicin—prostate cancer	4.28e-05	0.000193	CcSEcCtD
Orlistat—Asthenia—Capecitabine—prostate cancer	4.28e-05	0.000193	CcSEcCtD
Orlistat—Malaise—Doxorubicin—prostate cancer	4.25e-05	0.000192	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—prostate cancer	4.24e-05	0.000191	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—prostate cancer	4.23e-05	0.000191	CcSEcCtD
Orlistat—Urticaria—Prednisone—prostate cancer	4.22e-05	0.000191	CcSEcCtD
Orlistat—Pruritus—Capecitabine—prostate cancer	4.22e-05	0.000191	CcSEcCtD
Orlistat—Diarrhoea—Docetaxel—prostate cancer	4.22e-05	0.00019	CcSEcCtD
Orlistat—Body temperature increased—Prednisone—prostate cancer	4.2e-05	0.00019	CcSEcCtD
Orlistat—Abdominal pain—Prednisone—prostate cancer	4.2e-05	0.00019	CcSEcCtD
Orlistat—Palpitations—Doxorubicin—prostate cancer	4.16e-05	0.000188	CcSEcCtD
Orlistat—Oedema—Epirubicin—prostate cancer	4.16e-05	0.000188	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—prostate cancer	4.16e-05	0.000188	CcSEcCtD
Orlistat—Infection—Epirubicin—prostate cancer	4.13e-05	0.000186	CcSEcCtD
Orlistat—Cough—Doxorubicin—prostate cancer	4.11e-05	0.000186	CcSEcCtD
Orlistat—Convulsion—Doxorubicin—prostate cancer	4.08e-05	0.000184	CcSEcCtD
Orlistat—Diarrhoea—Capecitabine—prostate cancer	4.08e-05	0.000184	CcSEcCtD
Orlistat—Nervous system disorder—Epirubicin—prostate cancer	4.08e-05	0.000184	CcSEcCtD
Orlistat—Dizziness—Docetaxel—prostate cancer	4.07e-05	0.000184	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—prostate cancer	4.04e-05	0.000182	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—prostate cancer	4.02e-05	0.000181	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—prostate cancer	4.01e-05	0.000181	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—prostate cancer	4.01e-05	0.000181	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—prostate cancer	4e-05	0.000181	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.98e-05	0.00018	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—prostate cancer	3.96e-05	0.000179	CcSEcCtD
Orlistat—Dizziness—Capecitabine—prostate cancer	3.94e-05	0.000178	CcSEcCtD
Orlistat—Dry mouth—Doxorubicin—prostate cancer	3.92e-05	0.000177	CcSEcCtD
Orlistat—Vomiting—Docetaxel—prostate cancer	3.92e-05	0.000177	CcSEcCtD
Orlistat—Hypersensitivity—Prednisone—prostate cancer	3.91e-05	0.000177	CcSEcCtD
Orlistat—Rash—Docetaxel—prostate cancer	3.88e-05	0.000175	CcSEcCtD
Orlistat—Dermatitis—Docetaxel—prostate cancer	3.88e-05	0.000175	CcSEcCtD
Orlistat—Headache—Docetaxel—prostate cancer	3.86e-05	0.000174	CcSEcCtD
Orlistat—Oedema—Doxorubicin—prostate cancer	3.85e-05	0.000174	CcSEcCtD
Orlistat—Anaphylactic shock—Doxorubicin—prostate cancer	3.85e-05	0.000174	CcSEcCtD
Orlistat—Infection—Doxorubicin—prostate cancer	3.82e-05	0.000173	CcSEcCtD
Orlistat—Asthenia—Prednisone—prostate cancer	3.81e-05	0.000172	CcSEcCtD
Orlistat—Vomiting—Capecitabine—prostate cancer	3.79e-05	0.000171	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.79e-05	0.000171	CcSEcCtD
Orlistat—Nervous system disorder—Doxorubicin—prostate cancer	3.77e-05	0.00017	CcSEcCtD
Orlistat—Rash—Capecitabine—prostate cancer	3.76e-05	0.00017	CcSEcCtD
Orlistat—Pruritus—Prednisone—prostate cancer	3.76e-05	0.00017	CcSEcCtD
Orlistat—Insomnia—Epirubicin—prostate cancer	3.76e-05	0.00017	CcSEcCtD
Orlistat—Dermatitis—Capecitabine—prostate cancer	3.76e-05	0.00017	CcSEcCtD
Orlistat—Headache—Capecitabine—prostate cancer	3.74e-05	0.000169	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—prostate cancer	3.74e-05	0.000169	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—prostate cancer	3.73e-05	0.000169	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—prostate cancer	3.72e-05	0.000168	CcSEcCtD
Orlistat—Nausea—Docetaxel—prostate cancer	3.66e-05	0.000165	CcSEcCtD
Orlistat—Dyspepsia—Epirubicin—prostate cancer	3.66e-05	0.000165	CcSEcCtD
Orlistat—Diarrhoea—Prednisone—prostate cancer	3.64e-05	0.000164	CcSEcCtD
Orlistat—Decreased appetite—Epirubicin—prostate cancer	3.61e-05	0.000163	CcSEcCtD
Orlistat—Gastrointestinal disorder—Epirubicin—prostate cancer	3.59e-05	0.000162	CcSEcCtD
Orlistat—Fatigue—Epirubicin—prostate cancer	3.58e-05	0.000162	CcSEcCtD
Orlistat—Pain—Epirubicin—prostate cancer	3.55e-05	0.00016	CcSEcCtD
Orlistat—Nausea—Capecitabine—prostate cancer	3.54e-05	0.00016	CcSEcCtD
Orlistat—Dizziness—Prednisone—prostate cancer	3.51e-05	0.000159	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.5e-05	0.000158	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—prostate cancer	3.48e-05	0.000157	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—prostate cancer	3.45e-05	0.000156	CcSEcCtD
Orlistat—Feeling abnormal—Epirubicin—prostate cancer	3.42e-05	0.000155	CcSEcCtD
Orlistat—Gastrointestinal pain—Epirubicin—prostate cancer	3.4e-05	0.000153	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—prostate cancer	3.38e-05	0.000153	CcSEcCtD
Orlistat—Vomiting—Prednisone—prostate cancer	3.38e-05	0.000153	CcSEcCtD
Orlistat—Rash—Prednisone—prostate cancer	3.35e-05	0.000151	CcSEcCtD
Orlistat—Dermatitis—Prednisone—prostate cancer	3.35e-05	0.000151	CcSEcCtD
Orlistat—Decreased appetite—Doxorubicin—prostate cancer	3.34e-05	0.000151	CcSEcCtD
Orlistat—Headache—Prednisone—prostate cancer	3.33e-05	0.00015	CcSEcCtD
Orlistat—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.32e-05	0.00015	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—prostate cancer	3.32e-05	0.00015	CcSEcCtD
Orlistat—Urticaria—Epirubicin—prostate cancer	3.3e-05	0.000149	CcSEcCtD
Orlistat—Pain—Doxorubicin—prostate cancer	3.29e-05	0.000149	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—prostate cancer	3.29e-05	0.000148	CcSEcCtD
Orlistat—Abdominal pain—Epirubicin—prostate cancer	3.29e-05	0.000148	CcSEcCtD
Orlistat—Feeling abnormal—Doxorubicin—prostate cancer	3.17e-05	0.000143	CcSEcCtD
Orlistat—Nausea—Prednisone—prostate cancer	3.16e-05	0.000143	CcSEcCtD
Orlistat—Gastrointestinal pain—Doxorubicin—prostate cancer	3.14e-05	0.000142	CcSEcCtD
Orlistat—Hypersensitivity—Epirubicin—prostate cancer	3.06e-05	0.000138	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—prostate cancer	3.05e-05	0.000138	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—prostate cancer	3.04e-05	0.000137	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—prostate cancer	3.04e-05	0.000137	CcSEcCtD
Orlistat—Asthenia—Epirubicin—prostate cancer	2.98e-05	0.000135	CcSEcCtD
Orlistat—Pruritus—Epirubicin—prostate cancer	2.94e-05	0.000133	CcSEcCtD
Orlistat—Diarrhoea—Epirubicin—prostate cancer	2.84e-05	0.000128	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—prostate cancer	2.83e-05	0.000128	CcSEcCtD
Orlistat—Asthenia—Doxorubicin—prostate cancer	2.76e-05	0.000125	CcSEcCtD
Orlistat—Dizziness—Epirubicin—prostate cancer	2.75e-05	0.000124	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—prostate cancer	2.72e-05	0.000123	CcSEcCtD
Orlistat—Vomiting—Epirubicin—prostate cancer	2.64e-05	0.000119	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—prostate cancer	2.63e-05	0.000119	CcSEcCtD
Orlistat—Rash—Epirubicin—prostate cancer	2.62e-05	0.000118	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—prostate cancer	2.62e-05	0.000118	CcSEcCtD
Orlistat—Headache—Epirubicin—prostate cancer	2.6e-05	0.000118	CcSEcCtD
Orlistat—Dizziness—Doxorubicin—prostate cancer	2.54e-05	0.000115	CcSEcCtD
Orlistat—Nausea—Epirubicin—prostate cancer	2.47e-05	0.000111	CcSEcCtD
Orlistat—Vomiting—Doxorubicin—prostate cancer	2.44e-05	0.00011	CcSEcCtD
Orlistat—Rash—Doxorubicin—prostate cancer	2.42e-05	0.000109	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—prostate cancer	2.42e-05	0.000109	CcSEcCtD
Orlistat—Headache—Doxorubicin—prostate cancer	2.41e-05	0.000109	CcSEcCtD
Orlistat—Nausea—Doxorubicin—prostate cancer	2.28e-05	0.000103	CcSEcCtD
Orlistat—FASN—Disease—STAT3—prostate cancer	8.77e-06	5.16e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—prostate cancer	8.77e-06	5.16e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GGT1—prostate cancer	8.68e-06	5.11e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—prostate cancer	8.68e-06	5.11e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—prostate cancer	8.66e-06	5.1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ANXA1—prostate cancer	8.65e-06	5.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NCOA1—prostate cancer	8.55e-06	5.04e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRKCZ—prostate cancer	8.49e-06	5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP19A1—prostate cancer	8.43e-06	4.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—EP300—prostate cancer	8.29e-06	4.88e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—prostate cancer	8.26e-06	4.87e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—prostate cancer	8.26e-06	4.87e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—prostate cancer	8.21e-06	4.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PARP1—prostate cancer	8.2e-06	4.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR4—prostate cancer	8.2e-06	4.83e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—prostate cancer	8.19e-06	4.82e-05	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—prostate cancer	8.15e-06	4.8e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—RXRA—prostate cancer	8.14e-06	4.79e-05	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—prostate cancer	8.13e-06	4.79e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CALCA—prostate cancer	8.1e-06	4.77e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—prostate cancer	8.07e-06	4.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SRC—prostate cancer	8.06e-06	4.75e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—prostate cancer	8.05e-06	4.74e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—prostate cancer	7.99e-06	4.71e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—prostate cancer	7.99e-06	4.71e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—prostate cancer	7.99e-06	4.7e-05	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—prostate cancer	7.97e-06	4.69e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	7.91e-06	4.66e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL12—prostate cancer	7.91e-06	4.66e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—prostate cancer	7.89e-06	4.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—prostate cancer	7.85e-06	4.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—COMT—prostate cancer	7.84e-06	4.61e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—EP300—prostate cancer	7.83e-06	4.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTP1—prostate cancer	7.8e-06	4.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ITPR1—prostate cancer	7.68e-06	4.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—prostate cancer	7.55e-06	4.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CG—prostate cancer	7.53e-06	4.44e-05	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—prostate cancer	7.53e-06	4.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TST—prostate cancer	7.49e-06	4.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GRHL1—prostate cancer	7.49e-06	4.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CBR1—prostate cancer	7.49e-06	4.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADI1—prostate cancer	7.49e-06	4.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSAT1—prostate cancer	7.49e-06	4.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CSAD—prostate cancer	7.49e-06	4.41e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—prostate cancer	7.45e-06	4.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP9—prostate cancer	7.45e-06	4.39e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—prostate cancer	7.32e-06	4.31e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—prostate cancer	7.32e-06	4.31e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TYMS—prostate cancer	7.25e-06	4.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRKCQ—prostate cancer	7.22e-06	4.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NGFR—prostate cancer	7.22e-06	4.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—prostate cancer	7.21e-06	4.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—prostate cancer	7.17e-06	4.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAP3K7—prostate cancer	7.13e-06	4.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LPL—prostate cancer	7.04e-06	4.14e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UGT2B15—prostate cancer	6.96e-06	4.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UGT2B17—prostate cancer	6.96e-06	4.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CKMT2—prostate cancer	6.96e-06	4.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GRHPR—prostate cancer	6.96e-06	4.1e-05	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—prostate cancer	6.92e-06	4.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF10—prostate cancer	6.86e-06	4.04e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—prostate cancer	6.85e-06	4.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1A1—prostate cancer	6.8e-06	4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRB2—prostate cancer	6.79e-06	4e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—prostate cancer	6.75e-06	3.97e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—prostate cancer	6.75e-06	3.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ERCC2—prostate cancer	6.74e-06	3.97e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—prostate cancer	6.69e-06	3.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—prostate cancer	6.68e-06	3.93e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MAP2K1—prostate cancer	6.67e-06	3.93e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—prostate cancer	6.62e-06	3.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CD—prostate cancer	6.62e-06	3.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VAV3—prostate cancer	6.62e-06	3.9e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RFK—prostate cancer	6.54e-06	3.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AOX1—prostate cancer	6.54e-06	3.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM3—prostate cancer	6.54e-06	3.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SULT2B1—prostate cancer	6.54e-06	3.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MBTPS1—prostate cancer	6.54e-06	3.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PGAM2—prostate cancer	6.54e-06	3.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAGLU—prostate cancer	6.54e-06	3.85e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFBR2—prostate cancer	6.52e-06	3.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ITPR1—prostate cancer	6.42e-06	3.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—prostate cancer	6.34e-06	3.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARA—prostate cancer	6.22e-06	3.66e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP3A43—prostate cancer	6.2e-06	3.65e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AMACR—prostate cancer	6.2e-06	3.65e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SRD5A2—prostate cancer	6.2e-06	3.65e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—DEGS1—prostate cancer	6.2e-06	3.65e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAT1—prostate cancer	6.2e-06	3.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1R—prostate cancer	6.14e-06	3.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—prostate cancer	6.13e-06	3.61e-05	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—prostate cancer	6.13e-06	3.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—JAK2—prostate cancer	6.08e-06	3.58e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—prostate cancer	6.06e-06	3.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—prostate cancer	5.93e-06	3.49e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD17B1—prostate cancer	5.92e-06	3.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LPL—prostate cancer	5.88e-06	3.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAV1—prostate cancer	5.84e-06	3.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDGFRB—prostate cancer	5.83e-06	3.43e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—prostate cancer	5.79e-06	3.41e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CB—prostate cancer	5.77e-06	3.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ITGB3—prostate cancer	5.68e-06	3.35e-05	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—prostate cancer	5.65e-06	3.33e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—prostate cancer	5.59e-06	3.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.58e-06	3.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—prostate cancer	5.55e-06	3.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB3—prostate cancer	5.51e-06	3.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR2—prostate cancer	5.5e-06	3.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CG—prostate cancer	5.32e-06	3.13e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—prostate cancer	5.3e-06	3.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—prostate cancer	5.28e-06	3.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—B4GALT4—prostate cancer	5.28e-06	3.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HPGD—prostate cancer	5.28e-06	3.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIF1A—prostate cancer	5.05e-06	2.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—INS—prostate cancer	5.04e-06	2.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—prostate cancer	5.01e-06	2.95e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TNFRSF21—prostate cancer	4.96e-06	2.92e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CREBBP—prostate cancer	4.94e-06	2.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LEP—prostate cancer	4.93e-06	2.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CAV1—prostate cancer	4.89e-06	2.88e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—prostate cancer	4.83e-06	2.84e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP7B1—prostate cancer	4.82e-06	2.84e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTAP—prostate cancer	4.82e-06	2.84e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—prostate cancer	4.73e-06	2.79e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ESR1—prostate cancer	4.71e-06	2.77e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SULT1E1—prostate cancer	4.7e-06	2.77e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SRD5A1—prostate cancer	4.7e-06	2.77e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CD—prostate cancer	4.68e-06	2.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BAD—prostate cancer	4.6e-06	2.71e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ACSL4—prostate cancer	4.49e-06	2.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD17B3—prostate cancer	4.49e-06	2.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APC—prostate cancer	4.45e-06	2.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CG—prostate cancer	4.45e-06	2.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NOS3—prostate cancer	4.42e-06	2.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGF—prostate cancer	4.4e-06	2.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IRS1—prostate cancer	4.4e-06	2.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UMPS—prostate cancer	4.3e-06	2.53e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PHGDH—prostate cancer	4.3e-06	2.53e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ARG2—prostate cancer	4.3e-06	2.53e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GSK3B—prostate cancer	4.27e-06	2.51e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LDHB—prostate cancer	4.22e-06	2.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—INS—prostate cancer	4.21e-06	2.48e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP3A5—prostate cancer	4.14e-06	2.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CREBBP—prostate cancer	4.13e-06	2.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CB—prostate cancer	4.08e-06	2.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1—prostate cancer	4.08e-06	2.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—prostate cancer	4.06e-06	2.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—prostate cancer	4.04e-06	2.38e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TCN2—prostate cancer	4e-06	2.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA3—prostate cancer	4e-06	2.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UCP3—prostate cancer	4e-06	2.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PDHA1—prostate cancer	4e-06	2.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MAP2K1—prostate cancer	3.94e-06	2.32e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CD—prostate cancer	3.91e-06	2.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SERPINE1—prostate cancer	3.87e-06	2.28e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—prostate cancer	3.83e-06	2.26e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD3B1—prostate cancer	3.81e-06	2.25e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC22A3—prostate cancer	3.81e-06	2.25e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF2—prostate cancer	3.75e-06	2.21e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOS3—prostate cancer	3.69e-06	2.18e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA4—prostate cancer	3.66e-06	2.15e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.66e-06	2.15e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JAK2—prostate cancer	3.59e-06	2.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA2—prostate cancer	3.56e-06	2.1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—prostate cancer	3.52e-06	2.08e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.52e-06	2.07e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCG5—prostate cancer	3.52e-06	2.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—prostate cancer	3.52e-06	2.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MDM2—prostate cancer	3.51e-06	2.06e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—prostate cancer	3.46e-06	2.03e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTA1—prostate cancer	3.44e-06	2.02e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CB—prostate cancer	3.41e-06	2.01e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.4e-06	2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAT2—prostate cancer	3.4e-06	2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTO1—prostate cancer	3.4e-06	2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—EP300—prostate cancer	3.36e-06	1.98e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—prostate cancer	3.28e-06	1.93e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PLCB2—prostate cancer	3.26e-06	1.92e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LRP2—prostate cancer	3.26e-06	1.92e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.26e-06	1.92e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1B—prostate cancer	3.2e-06	1.88e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—P4HB—prostate cancer	3.2e-06	1.88e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—prostate cancer	3.14e-06	1.85e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—prostate cancer	3.13e-06	1.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—prostate cancer	3.12e-06	1.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.11e-06	1.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCND1—prostate cancer	3.05e-06	1.8e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.03e-06	1.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CTNNB1—prostate cancer	3.02e-06	1.78e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MED12—prostate cancer	2.98e-06	1.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—prostate cancer	2.96e-06	1.75e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNG5—prostate cancer	2.96e-06	1.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN1A—prostate cancer	2.95e-06	1.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—prostate cancer	2.95e-06	1.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—prostate cancer	2.88e-06	1.69e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOA3—prostate cancer	2.85e-06	1.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EP300—prostate cancer	2.81e-06	1.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SRC—prostate cancer	2.73e-06	1.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HPGDS—prostate cancer	2.72e-06	1.6e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.7e-06	1.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—prostate cancer	2.66e-06	1.57e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTT1—prostate cancer	2.64e-06	1.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ACHE—prostate cancer	2.64e-06	1.55e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—prostate cancer	2.64e-06	1.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.61e-06	1.53e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.53e-06	1.49e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PRKACB—prostate cancer	2.52e-06	1.48e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.5e-06	1.47e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—prostate cancer	2.49e-06	1.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—prostate cancer	2.45e-06	1.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—prostate cancer	2.44e-06	1.44e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—prostate cancer	2.4e-06	1.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOA2—prostate cancer	2.38e-06	1.4e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.27e-06	1.34e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—prostate cancer	2.26e-06	1.33e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.22e-06	1.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NQO1—prostate cancer	2.19e-06	1.29e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TH—prostate cancer	2.16e-06	1.27e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.1e-06	1.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—prostate cancer	2.08e-06	1.22e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GGT1—prostate cancer	2.03e-06	1.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—prostate cancer	2.03e-06	1.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—prostate cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOA1—prostate cancer	2e-06	1.18e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.97e-06	1.16e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RXRA—prostate cancer	1.91e-06	1.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—prostate cancer	1.84e-06	1.08e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—COMT—prostate cancer	1.84e-06	1.08e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTP1—prostate cancer	1.83e-06	1.08e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ITPR1—prostate cancer	1.8e-06	1.06e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TYMS—prostate cancer	1.7e-06	1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—prostate cancer	1.7e-06	1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—prostate cancer	1.68e-06	9.88e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LPL—prostate cancer	1.65e-06	9.7e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.59e-06	9.37e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ERCC2—prostate cancer	1.58e-06	9.29e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—prostate cancer	1.48e-06	8.74e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARA—prostate cancer	1.46e-06	8.57e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAV1—prostate cancer	1.37e-06	8.06e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.25e-06	7.34e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—INS—prostate cancer	1.18e-06	6.95e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CREBBP—prostate cancer	1.16e-06	6.8e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.1e-06	6.45e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NOS3—prostate cancer	1.03e-06	6.09e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CB—prostate cancer	9.55e-07	5.62e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—prostate cancer	9.46e-07	5.57e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—prostate cancer	8.25e-07	4.86e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—EP300—prostate cancer	7.87e-07	4.63e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.82e-07	3.43e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—prostate cancer	4.76e-07	2.8e-06	CbGpPWpGaD
